1120 related articles for article (PubMed ID: 33109754)
41. Epigenetic lifestyle of Epstein-Barr virus.
Buschle A; Hammerschmidt W
Semin Immunopathol; 2020 Apr; 42(2):131-142. PubMed ID: 32232535
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
Martin KA; Lupey LN; Tempera I
J Virol; 2016 Oct; 90(19):8520-30. PubMed ID: 27440880
[TBL] [Abstract][Full Text] [Related]
43. The danger molecule HMGB1 cooperates with the NLRP3 inflammasome to sustain expression of the EBV lytic switch protein in Burkitt lymphoma cells.
Reinhart NM; Akinyemi IA; Frey TR; Xu H; Agudelo C; Brathwaite J; Burton EM; Burgula S; McIntosh MT; Bhaduri-McIntosh S
Virology; 2022 Jan; 566():136-142. PubMed ID: 34922257
[TBL] [Abstract][Full Text] [Related]
44. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
45. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
46. Regulation of the latent-lytic switch in Epstein-Barr virus.
Kenney SC; Mertz JE
Semin Cancer Biol; 2014 Jun; 26():60-8. PubMed ID: 24457012
[TBL] [Abstract][Full Text] [Related]
47. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr Virus miR-BHRF1-3 Targets the BZLF1 3'UTR and Regulates the Lytic Cycle.
Fachko DN; Chen Y; Skalsky RL
J Virol; 2022 Feb; 96(4):e0149521. PubMed ID: 34878852
[TBL] [Abstract][Full Text] [Related]
49. miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas.
Cao P; Zhang M; Wang L; Sai B; Tang J; Luo Z; Shuai C; Zhang L; Li Z; Wang Y; Li G; Xiang J
BMC Cancer; 2018 Dec; 18(1):1293. PubMed ID: 30594162
[TBL] [Abstract][Full Text] [Related]
50. Regulation of Epstein-Barr Virus Life Cycle and Cell Proliferation by Histone H3K27 Methyltransferase EZH2 in Akata Cells.
Ichikawa T; Okuno Y; Sato Y; Goshima F; Yoshiyama H; Kanda T; Kimura H; Murata T
mSphere; 2018 Nov; 3(6):. PubMed ID: 30487153
[TBL] [Abstract][Full Text] [Related]
51. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.
Daigle D; Megyola C; El-Guindy A; Gradoville L; Tuck D; Miller G; Bhaduri-McIntosh S
J Virol; 2010 Jan; 84(2):993-1004. PubMed ID: 19889776
[TBL] [Abstract][Full Text] [Related]
52. A molecular link between malaria and Epstein-Barr virus reactivation.
Chêne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
[TBL] [Abstract][Full Text] [Related]
53. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
54. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
[TBL] [Abstract][Full Text] [Related]
55. Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.
Imai K; Kamio N; Cueno ME; Saito Y; Inoue H; Saito I; Ochiai K
FEBS J; 2014 May; 281(9):2148-58. PubMed ID: 24588869
[TBL] [Abstract][Full Text] [Related]
56. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr Virus Lytic Cycle Reactivation.
McKenzie J; El-Guindy A
Curr Top Microbiol Immunol; 2015; 391():237-61. PubMed ID: 26428377
[TBL] [Abstract][Full Text] [Related]
58. A role for the nucleosome assembly proteins TAF-Iβ and NAP1 in the activation of BZLF1 expression and Epstein-Barr virus reactivation.
Mansouri S; Wang S; Frappier L
PLoS One; 2013; 8(5):e63802. PubMed ID: 23691099
[TBL] [Abstract][Full Text] [Related]
59. Nascent Transcriptomics Reveal Cellular Prolytic Factors Upregulated Upstream of the Latent-to-Lytic Switch Protein of Epstein-Barr Virus.
Frey TR; Brathwaite J; Li X; Burgula S; Akinyemi IA; Agarwal S; Burton EM; Ljungman M; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941784
[TBL] [Abstract][Full Text] [Related]
60. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
Almohammed R; Osborn K; Ramasubramanyan S; Perez-Fernandez IBN; Godfrey A; Mancini EJ; Sinclair AJ
J Gen Virol; 2018 Jun; 99(6):805-817. PubMed ID: 29580369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
